XELOX vs. FOLFOX in metastatic colorectal cancer: An updated meta-analysis

References

• Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics. CA Cancer J Clin 2005;55:10–30.
   PubMed Web of Science ®Google Scholar
• Hoff PM, Ansari R, Batist G, Cox J, Kocha W, Kuperminc M, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-1ine treatment in 605 patients with metastatic colorectal cancer-results of a randomized phase III study. J Clin Oncol 2001;19:282–2292.
   Google Scholar
• Van Cutsem E, Twelves C, Cassidy J, Allman D, Bajetta E, Boyer M, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patient with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001;19:4097–4l06.
   PubMed Web of Science ®Google Scholar
• Andre T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, et al. Improved Overall Survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC Trial. J Clin Oncol 2009;27:3109–3116.
   PubMed Web of Science ®Google Scholar
• Haller DG, Cassidy J, Tabernero J, Maroun JA, De Braud FG, Price TJ, et al. Efficacy findings from a randomized phase III trial of capecitabine plus oxaliplatin versus bolus 5-FU/LV for stage III colon cancer (NO16968): impact of age on disease-free survival. J Clin Oncol 2010;28:3521.
   Google Scholar
• Zhang C, Wang J, Gu H, Zhu D, Li Y, Zhu P, et al. Capecitabine plus oxaliplatin compared with 5-fluorouracil plus oxaliplatin in metastatic colorectal cancer: meta-analysis of randomized controlled trials. Oncol Lett. 2012;3(4):831–838.
   PubMed Web of Science ®Google Scholar
• Zhao G, Gao P, Yang KH, Tian JH, Ma B. Capecitabine/oxaliplatin as first-line treatment for metastatic colorectal cancer: a meta-analysis. Colorectal Dis 2010;12(7):615–623.
   PubMed Web of Science ®Google Scholar
• Cao Y, Liao C, Tan A, Liu L, Mo Z, Gao F. Capecitabine plus oxaliplatin vs fluorouracil plus oxaliplatin as first line treatment for metastatic colorectal cancer - meta-analysis of six randomized trials. Colorectal Dis 2010;12(1):16–23.
   PubMed Web of Science ®Google Scholar
• Arkenau HT, Arnold D, Cassidy J, Diaz-Rubio E, Douillard JY, Hochster H, et al. Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials. J Clin Oncol 2008;26(36):5910–5917.
   PubMed Web of Science ®Google Scholar
• Available at http://www.ctep.cancer.gov.
   Google Scholar
• Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1–12.
   PubMedGoogle Scholar
• Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. Br Med J 1997;315:629–634.
   PubMed Web of Science ®Google Scholar
• Sterne JAC, Egger M, Smith GD. Systematic reviews in health care: investigating and dealing with publication and other biases in meta-analysis. BMJ 2001;323:101–105.
   PubMed Web of Science ®Google Scholar
• Cochrane IMS, Available at http://tech.cochrane.org/revman/download.
   Google Scholar
• Cassidy J, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. Br J Cancer 2011;28:58–64.
   Google Scholar
• Sastre J, Aranda E, Massutí B, Tabernero J, Chaves M, Abad A, et al. Elderly patients with advanced colorectal cancer derive similar benefit without excessive toxicity after first-line chemotherapy with oxaliplatin-based combinations: comparative outcomes from the 03-TTD-01 phase III study. Crit Rev Oncol 2009;70:134–144.
   PubMed Web of Science ®Google Scholar
• Cassidy J, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 2008;26:2006–2012.
   PubMed Web of Science ®Google Scholar
• Díaz-Rubio E, Tabernero J, Gómez-España A, Massutí B, Sastre J, Chaves M, et al. Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial. J Clin Oncol 2007;20:4224–4230.
   Google Scholar
• Ducreux M, Bennouna J, Hebbar M, Ychou M, Lledo G, Conroy T, et al. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer. Int J Cancer 2011;128:682–690.
   PubMed Web of Science ®Google Scholar
• Comella P, Massidda B, Filippelli G, Farris A, Natale D, Barberis G, et al. Randomised trial comparing biweekly oxaliplatin plus oral capecitabine versus oxaliplatin plus i.v. bolus fluorouracil/leucovorin in metastatic colorectal cancer patients: results of the Southern Italy Cooperative Oncology study 0401. J Clin Oncol 2009;135:217–226.
   Web of Science ®Google Scholar
• Rothenberg ML, Cox JV, Butts C, Navarro M, Bang YJ, Goel R, et al. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study. Ann Oncol. 2008;19:1720–1726.
   PubMed Web of Science ®Google Scholar
• Porschen R, Arkenau HT, Kubicka S, Greil R, Seufferlein T, Freier W, et al. Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. J Clin Oncol. 2007;25:4217–4223.
   PubMed Web of Science ®Google Scholar
• Martoni AA, Pinto C, Di Fabio F, Lelli G, Rojas Llimpe FL, Gentile AL, et al. Capecitabine plus oxaliplatin (xelox) versus protracted 5-fluorouracil venous infusion plus oxaliplatin (pvifox) as first-line treatment in advanced colorectal cancer: a GOAM phase II randomised study (FOCA trial). Eur J Cancer 2006;42:3161–3168.
   PubMed Web of Science ®Google Scholar
• Arkenau HT, Graeven U, Kubicka S, Grothey A, English-Fritz C, Kretzschmar A, et al. Oxaliplatin in Combination with 5-Fluorouracil/Leucovorin or Capecitabin in Elderly Patients with metastatic colorectal cancer. Clin Colorectal Cancer 2008;7:60–64.
   PubMed Web of Science ®Google Scholar
• Kidwell KM, Yothers G, Ganz PA, Land SR, Ko CY, Cecchini RS, et al. Long-term neurotoxicity effects of oxaliplatin added to fluorouracil and leucovorin as adjuvant therapy for colon cancer: results from National Surgical Adjuvant Breast and Bowel Project trials C-07 and LTS-01. Cancer 2012;118:5614–5622.
   PubMed Web of Science ®Google Scholar
• Tournigand C, Cervantes A, Figer A, Lledo G, Flesch M, Buyse M, et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop and-go fashion in advanced colorectal cancer–a GERCOR study. J Clin Oncol 2006;24:394–400.
   PubMed Web of Science ®Google Scholar
• Haller DG, Cassidy J, Clarke SJ, Cunningham D, Van Cutsem E, Hoff PM, et al. Potential regional differences for the tolerability profiles of fluoropyrimidines. J Clin Oncol 2008;26:2118–2123.
   PubMed Web of Science ®Google Scholar
• Hochster HS, Hart LL, Ramanathan RK, Hainsworth JD, Hedrick EE, Childs BH. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol 2008;26:3523–3529.
   PubMed Web of Science ®Google Scholar
• Schmoll H-J, Arnold D. Update on capecitabine in colorectal cancer. Oncologist 2006;11:1003–1009.
   PubMed Web of Science ®Google Scholar
• Hofheinz RD, Heinemann V, von Weikersthal LF, Laubender RP, Gencer D, Burkholder I, et al. Capecitabine-associated hand-foot-skin reaction is an independent clinical predictor of improved survival in patients with colorectal cancer. Br J Cancer 2012;107:1678–1683.
   PubMed Web of Science ®Google Scholar
• Conroy T, Hebbar M, Bennouna J, Ducreux M, Ychou M, Lledo G, et al. Quality of life findings from a randomized phase III study of XELOX versus FOLFOX-6 in metastatic colorectal cancer. Br J Cancer 2010;102:59–67.
   PubMed Web of Science ®Google Scholar
• Perrocheau G, Bennouna J, Ducreux M, Hebbar M, Ychou M, Lledo G, et al. Cost-minimization analysis of a phase III study of capecitabine+oxaliplatin vs. infusional 5-FU/folinic acid (FA)+oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer (MCRC) in the French setting. J Clin Oncol 2007;25(18 suppl):184s (Abstract 4083).
   Google Scholar
• Mayer RJ. Should Capecitabine replace infusional fluorouracil and leucovorin when combined with oxaliplatin in metastatic colorectal cancer? J Clin Oncol 2007;27:4164–4167.
   Google Scholar
• Saltz LB, Clarke S, Diaz-Rubio W, Scheithauser A, Figer R, Wong S, et al. Bevacizumab (Bev) in combination with XELOX or FOLFOX4: efficacy results from XELOX-1/NO16966, a randomized phase III trial in the Wrst-line metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol Gastrointestinal Cancer Symposium 2007. (abstract 238)
   Google Scholar
• The NCCN Guidelines for Colon and Rectal Cancer, Available at www.NCCN.org.
   Google Scholar